Jaén-Moreno, María José
Feu, Nuria
Redondo-Écija, Justa
Montiel, Francisco Javier
Gómez, Cristina
del Pozo, Gloria I.
Alcalá, Jose Ángel
Gutiérrez-Rojas, Luis
Balanzá-Martinez, Vicente
Chauca, Geli Marie
Carrión, Laura
Osuna, Maria Isabel
Sánchez, María Dolores
Caro, Inmaculada
Ayora, Miriam
Valdivia, Francisca
López, María Soledad
Poyato, Jose Manuel
Sarramea, Fernando
Funding for this research was provided by:
Instituto de Salud Carlos III (PI16/00802)
Article History
Received: 8 August 2018
Accepted: 15 December 2018
First Online: 14 January 2019
Ethics approval and consent to participate
: The study protocol has been approved by the Ethics Committee of Reina Sofía Hospital in Córdoba, Spain, and informed consent will be obtained from each participating patient before recruitment.
: Not applicable.
: VB-M. has received grants and served as consultant, advisor or continuing medical education (CME) speaker during the last 5 years for the following entities: Angelini Spain, Angelini Portugal, AstraZeneca, Bristol-Myers-Squibb, Ferrer, Janssen. Juste, Lundbeck, Nutrición Médica, and Otsuka. JA Alcalá-Partera has served as advisor to: Adamed, Lundbeck, Otsuka, Janssen-Cilag, Pfizer, Rovi y Servier; and as speaker to: Janssen-Cilag, Pfizer y Servier. L. Gutiérrez-Rojas has been a spokesperson for, and advisory board member of, Bristol-Myers Squibb, Janssen-Cilag, Astra-Zeneca, Rovi, Lundbeck, Otsuka, GSK and Pfizer. All other researchers report no biomedical financial interests or potential conflicts of interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.